BioCentury
ARTICLE | Company News

Orexo, J&J deal

February 6, 2012 8:00 AM UTC

Orexo and Johnson & Johnson's Janssen Pharmaceuticals Inc. (formerly Ortho-McNeil-Janssen Pharmaceuticals Inc.) and Janssen Pharmaceutica N.V. subsidiaries, mutually terminated a 2010 deal granting the subsidiaries exclusive, worldwide rights to develop and commercialize Orexo's OX-CLI and OX-ESI programs, plus a third undisclosed program from J&J. Details were not disclosed (see BioCentury, June 7, 2010). ...